Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial

Lancet

Volumn 368, Issue 9544, 2006, Pages 1339-1348

  Vora, Ajay ^a   Mitchell, Chris D ^b   Lennard, Lynne ^c   Eden, TOB ^d   Kinsey, Sally E ^e   Lilleyman, John ^f   Richards, Sue M ^g  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f ROYAL LONDON HOSPITAL   (United Kingdom)

^g CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; DEXAMETHASONE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG FATALITY; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; HEPATITIS; HEPATOMEGALY; HEPATOPULMONARY SYNDROME; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LIVER FIBROSIS; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; LUNG DISEASE; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NODULAR HYPERPLASIA; PORTAL HYPERTENSION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK; SPLENOMEGALY; THROMBOCYTOPENIA; UNITED KINGDOM;

EID: 33749515604     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69558-5     Document Type: Article

References (39)

1. Burchenal J., Murphy M., Ellison R., et al. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood 8 (1953) 965-999
2. Murphy M., Tan C., Ellison R., Karnofsky D., and Burchenal J. Clinical evaluation of chloroquine and thioguanine. Proc Am Assoc Cancer Res 2 (1955) 36-39
3. Brox L., Birkett L., and Belch A. Clinical pharmacology of oral thioguanine in acute myelogenous leukemia. Cancer Chemother Pharmacol 6 (1981) 35-38
4. Nelson J. Mechanism of actions of thiopurines used in curative therapy for childhood leukemias. Cancer Bull 44 (1992) 470-473
5. Lennard L., Davies H., and Lilleyman J. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?. Br J Cancer 68 (1993) 186-190
6. Adamson P., Poplack D., and Balis F. The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia. Leuk Res 18 (1994) 805-810
7. Evans W., and Relling M. Mercaptopurine vs thioguanine for the treatment of acute lymphoblastic leukemia. Leuk Res 18 (1994) 811-814
8. Chessells J., Richards S., Bailey C., Lilleyman J., and Eden O. Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials. Br J Haematol 89 (1995) 364-372
9. Kinsey S., Mitchell C., Harrison G., and Richards S. Treatment of HIgh Risk Leukaemia-Results of MRC Childhood Acute Lymphoblastic Leukaemia Study MRC HR-1. Blood 100 (2002) 763a
10. Mitchell C., Richards S., Kinsey S., et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 129 (2005) 734-745
11. Hann I., Vora A., Harrison G., et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol 113 (2001) 103-114
12. Chessells J., Harrison G., Richards S., et al. Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI. Br J Haematol 118 (2002) 445-455
13. Eden O., Harrison G., Richards S., et al. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party. Leukemia 14 (2000) 2307-2320
14. Bostrom B., Sensel M., Sather H., et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 101 (2003) 3809-3817
15. Tubergen D., Gilchrist G., O'Brien R., et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. J Clin Oncol 11 (1993) 527-537
16. Nachman J., Sather H., Sensel M., et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338 (1998) 1663-1671
17. Stork L., Sather H., Hutchinson R., et al. Comparison of mercaptopurine with thioguanine and IT methotrexate with IT "Triples" (ITT) in children with standard risk ALL: results of CCG-1952 (2002), American Society of Hematology
18. McDonald G., Sharma P., Matthews D., Shulman H., and Thomas E. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 4 (1984) 116-122
19. Harms D., Gobel U., Spaar H., et al. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood 102 (2003) 2736-2740
20. Henze G., Fengler R., Hartmann R., et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85): a relapse study of the BFM group. Blood 78 (1991) 1166-1172
21. Bairey O., Kirgner I., Yakobi M., et al. Clinical severe hepatic venoocclusive disease during induction treatment of acute monoblastic leukemia managed with defibrotide. Am J Hematol 69 (2002) 281-284
22. D'Cruz C., Wimmer R., Harcke H., Huff D., and Naiman J. Veno-occlusive disease of the liver in children following chemotherapy for acute myelocytic leukemia. Cancer 52 (1983) 1803-1807
23. Gill R., Onstad G., Cardamone J., Maneval D., and Sumner H. Hepatic veno-occlusive disease caused by 6-thioguanine. Ann Intern Med 96 (1982) 58-60
24. Griner P., Elbadawi A., and Packman C. Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases. Ann Intern Med 85 (1976) 578-582
25. Krivoy N., Raz R., Carter A., and Alroy G. Reversible hepatic veno-occlusive disease and 6-thioguanine. Ann Intern Med 96 (1982) 788
26. Larrey D., Freneaux E., Berson A., et al. Peliosis hepatis induced by 6-thioguanine administration. Gut 29 (1988) 1265-1269
27. Merino J., Casanova F., Saez-Royuela F., Velasco A., and Gonzalez J. Veno-occlusive disease of the liver associated with thiopurines in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 17 (2000) 429-431
28. Dubinsky M., Vasiliauskas E., Singh H., et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 125 (2003) 298-303
29. Kao N., and Rosenblate H. 6-Thioguanine therapy for psoriasis causing toxic hepatic venoocclusive disease. J Am Acad Dermatol 28 (1993) 1017-1018
30. Holtmann M., Schreiner O., Kohler H., et al. Veno-occlusive disease (VOD) in Crohn's disease (CD) treated with azathioprine. Dig Dis Sci 48 (2003) 1503-1505
31. Broxson E., Dole M., Wong R., Laya B., and Stork L. Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy. Pediatr Blood Cancer 44 (2005) 226-231
32. De Bruyne R., Portmann B., Samyn M., et al. Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia. J Hepatol 44 (2006) 407-410
33. Rozman C., Carreras E., Qian C., et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant 17 (1996) 75-80
34. Park Y., Yasui M., Yoshimoto T., et al. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant 19 (1997) 915-920
35. Bisogno G., de Kraker J., Weirich A., et al. Veno-occlusive disease of the liver in children treated for Wilms tumor. Med Pediatr Oncol 29 (1997) 245-251
36. Boula A., Mantadakis E., Xilouri I., et al. Veno-occlusive disease of the liver associated with chronic myelomonocytic leukemia treated with vincristine and standard doses of cytarabine. Am J Hematol 79 (2005) 216-219
37. Essell J., Thompson J., Harman G., et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 79 (1992) 2784-2788
38. Guilland J., Favier A., Potier d., Galan P., and Hercberg S. Hyperhomocysteinemia: an independent risk factor or a simple marker of vascular disease? 1 basic data. Pathol Biol 51 (2003) 101-110
39. Stoneham S., Lennard L., Coen P., Lilleyman J., and Saha V. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematol 123 (2003) 100-102